Sunday, October 06, 2013 5:52:48 PM
Notwithstanding the unanticipated placebo effect, I have remained a firm believer in a future of Libigel.
I believe the test protocols were at fault for the high placebo outcome. I am now an avid believer in ATRS, but I think Libigel will ultimately prove to be its most valuable asset. What I don't know, and perhaps you can help, what was the nature of the agreement between Antares and Biosante? I would imagine that if Anip conveys it's interest in the drug, Antares will remain a beneficiary to the same extent. If some third-party pursues the patents you spoke of, do you know how Antares will stand. I'm a newcomer to ATRS but I believe Libigel will be a big part of it's future.
It was a pleasure reading your post. It appears that you share some of my sentiments about Libigel.
FEATURED Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • Jun 14, 2024 2:07 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM